The rising incidence of various cancers, rising demand for monoclonal antibodies, and strong demand for affordable biosimilars, recombinant glycosylated proteins are currently dominating the market. The use of biosimilar monoclonal antibodies for the treatment of cancer has significantly increased due to their accessibility and low cost, whereas the use of biosimilar insulins has decreased globally.
Biosimilars Market non-glycosylated proteins held a sizable market share in 2021 in terms of product. The groupings include interferons, insulin, granulocyte colony stimulating factor, and recombinant human growth factor. Recombinant non-glycosylation is the non-glycosylation of active compounds produced by bacteria, preserving the active substance's biological activity. Recombinant non-glycosylated proteins known as biosimilars are necessary for the treatment of chronic diseases, which are becoming more common.
Read more @ https://creativeedge16.blogspot.com/2022/10/biosimilars-market-emerging-demands.html
